A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).
The aim of the reported trial was to investigate the safety and efficacy of memantine in mild to moderate vascular dementia (VaD). This was a 28-week, double-blind, parallel, randomized controlled trial of memantine 20 mg daily versus placebo which was conducted in 54 centres in the UK. Memantine is...
| Автори: | , , |
|---|---|
| Формат: | Journal article |
| Мова: | English |
| Опубліковано: |
2002
|